Pfizer awarded $3.5 billion contract by U.S. Army to produce COVID-19 vaccines

  • The Pentagon said on Monday that the U.S. Army has awarded Pfizer (NYSE:PFE) a contract valued at $3.5B to manufacture 500M doses of the vaccine developed by the company in partnership with BioNTech (NASDAQ:BNTX), New York Post reports.
  • The vaccine deliveries will be earmarked for distribution around the world by the end of next year. Pfizer 's messenger-RNA-based vaccine became the first COVID-19 shot to win the FDA's emergency use authorization in December last year.
  • A few days later, the U.S. government increased its order size for the vaccine by 100M doses, bringing the total number of its orders to 200M doses.
  • In June, it was reported that Pfizer (PFE) agreed to supply the federal government with 500M doses of the vaccine with an option for another 200M doses.
  • The company was set to make the deliveries at a not-for-profit basis, unlike the $19.50 per shot paid by the U.S. in the initial contract.

    For this year the company, based in New York City revenue will be around 81.23 billion USD. This is according to the average of the analysts' estimates. This is hugely more than 2021's revenue of 41.91 billion USD.

    Historical revenues and results Pfizer plus estimates 2021

    aandeel

    The analysts expect for 2021 a net profit of 23.42 billion USD. For this year most of the analysts expect a profit per share of 4.12 USD. With this the price/earnings-ratio is 11.24.

    Huge dividend Pfizer

    Analysts expect a dividend of 1.57 USD per share. Thus the dividend yield equals 3.39 percent. The average dividend yield of the pharmaceutical companies is a low 1.36 percent.

    Newest target prices around 43 USD

    The most recent recommendations for the pharmaceutical company are from Goldman Sachs , JP Morgan and Barclays .

    Pfizer 's market capitalization is based on the number of outstanding shares around 256.28 billion USD. 33

    Historical stock prices Pfizer

    historical stocks pfizer

    At 22.02 the stock trades 2.01 percent higher at 46.31 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.